Sterilization Monitoring Market: as the EPA’s January 2025 ethylene oxide rule makes continuous stationary indoor monitoring a binding regulatory requirement rather than a best-practice recommendation, sterilization monitoring is completing its transition from a periodic, batch-based compliance check into an always-on verification infrastructure that sterilization facilities must operate continuously to remain in regulatory compliance, so monitoring technology providers capable of delivering genuinely continuous, IoT-integrated verification, not just faster periodic readouts, are positioned to capture the specific compliance mandate this new rule creates.

The global sterilization monitoring market size was USD 1.06 Billion in 2025 and is expected to register a revenue CAGR of 7.5% during the forecast period. Market revenue growth is driven by factors such as the EPA’s January 2025 ethylene oxide rule converting continuous facility monitoring from a best practice into a binding regulatory requirement, rapid-read biological indicator adoption converting sterile processing verification from a delayed batch process into a same-shift decision tool, and low-temperature sterilization method proliferation creating demand for method-specific monitoring product line extensions. The first driving factor is the EPA’s January 2025 ethylene oxide rule, which converts continuous facility monitoring from a voluntary best practice into a binding regulatory requirement for ethylene oxide sterilization facilities specifically. The EPA published its Interim Registration Review Decision for ethylene oxide in January 2025, requiring medical device sterilization facilities to conduct continuous stationary indoor monitoring alongside new engineering controls and stricter occupational exposure limits. The second driving factor is rapid-read biological indicator adoption, converting sterile processing compliance verification from a delayed, multi-hour or multi-day batch process into a same-shift decision tool that sterile processing departments can act on immediately. Rapid-read biological indicator technology has compressed sterility verification turnaround time substantially relative to traditional multi-day culture-based biological indicators, allowing sterile processing departments to confirm sterilization cycle success and release instrument sets for use within the same clinical shift. The third driving factor is low-temperature sterilization method proliferation, including vaporised hydrogen peroxide and plasma sterilization, creating demand for method-specific monitoring product line extensions beyond traditional steam and ethylene oxide monitoring products. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a binding continuous monitoring regulatory requirement widens the addressable market for IoT-integrated cycle documentation platforms beyond what voluntary best-practice adoption alone would generate, letting the compliance mandate itself become the primary demand driver rather than facilities adopting continuous monitoring purely as a discretionary quality improvement investment. Once continuous stationary indoor monitoring becomes a binding regulatory requirement rather than a discretionary best practice, every ethylene oxide sterilization facility subject to the rule must adopt compliant continuous monitoring infrastructure regardless of its own internal quality improvement priorities, so the EPA’s January 2025 rule converts what had been a voluntary adoption decision into a mandatory compliance purchase across the entire regulated ethylene oxide sterilization facility population. As a result, demand for continuous monitoring and IoT-integrated cycle documentation platforms is concentrating specifically around ethylene oxide sterilization facilities working toward the EPA’s compliance requirements, and the forecast tilts toward continuous monitoring technology capturing a larger share of overall sterilization monitoring market revenue than periodic biological and chemical indicator products alone would generate. For instance, the EPA’s January 2025 Interim Registration Review Decision requires medical device sterilization facilities to conduct continuous stationary indoor monitoring as a binding compliance requirement, directly converting facility-level monitoring technology adoption from a discretionary investment into a regulatory necessity for every ethylene oxide sterilization facility working toward compliance ahead of the extended April 2028 deadline. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the EPA’s new binding requirement for continuous stationary indoor monitoring at ethylene oxide sterilization facilities, converting adoption from a discretionary quality improvement decision into a mandatory compliance purchase. A regulatory requirement that every regulated facility must comply with, regardless of its own internal technology adoption priorities, generates a fundamentally different demand pattern than voluntary best-practice adoption, since it removes the discretionary element from the purchasing decision entirely, so the EPA’s binding rule and near-universal continuous monitoring technology adoption across regulated ethylene oxide facilities are directly linked. The EPA published its Interim Registration Review Decision for ethylene oxide in January 2025, requiring medical device sterilization facilities to conduct continuous stationary indoor monitoring alongside new engineering controls and a stricter occupational exposure limit. The effect on the market is that continuous monitoring and IoT-integrated cycle documentation technology adoption is shifting from a discretionary investment decision to a regulatory compliance necessity specifically for ethylene oxide sterilization facilities. These are some of the key factors driving revenue growth of the market.

The second driver is the compression of sterility verification turnaround time that rapid-read biological indicator technology has achieved relative to traditional culture-based biological indicators. A sterile processing department that must wait multiple days for traditional culture-based biological indicator results cannot release a sterilized instrument set for immediate clinical use without either accepting delay or relying on process indicators alone, while rapid-read technology allows same-shift release decisions, and this immediate operational benefit is what has driven rapid, sustained rapid-read biological indicator adoption across hospital sterile processing departments. Rapid-read biological indicator technology has substantially compressed sterility verification turnaround time relative to traditional multi-day culture-based biological indicators, allowing sterile processing departments to confirm sterilization cycle success and release instrument sets within the same clinical shift. The effect on the market is that rapid-read technology is converting sterilization monitoring from a periodic, delayed audit function into an operationally integrated, same-shift verification workflow. These are some of the key factors driving revenue growth of the market.

“The EPA’s January 2025 Interim Registration Review Decision for ethylene oxide made continuous stationary indoor monitoring a binding regulatory requirement rather than a discretionary best practice, converting sterilization monitoring technology adoption from a voluntary quality improvement decision into a mandatory compliance purchase for every regulated ethylene oxide sterilization facility.”

The third driver is the continued proliferation of low-temperature sterilization methods, including vaporised hydrogen peroxide and plasma sterilization, each of which requires its own dedicated, clinically validated monitoring product. A biological or chemical indicator validated for steam sterilization cannot simply be repurposed for a low-temperature sterilization method, since each method’s specific sterilization mechanism requires its own dedicated monitoring product validation, and this method-specificity is what is driving monitoring product manufacturers to continuously extend their product lines as new low-temperature sterilization methods gain clinical adoption. Growing adoption of low-temperature sterilization methods, driven partly by the broader industry shift away from ethylene oxide, continues to create demand for dedicated, method-specific monitoring product line extensions across the sterilization monitoring product portfolio. The effect on the market is that sterilization monitoring product line breadth is becoming an increasingly important competitive differentiator as the underlying sterilization method landscape itself continues to diversify. These are some of the key factors driving revenue growth of the market.

However, the sterilization monitoring market faces adoption constraints from the capital and integration cost of upgrading from periodic to continuous monitoring infrastructure, low-temperature sterilization method proliferation requiring dedicated, method-specific monitoring product validation, and sterile processing staff training requirements for new monitoring workflow adoption. Because upgrading from periodic biological and chemical indicator-based monitoring to continuous, IoT-integrated cycle documentation infrastructure requires meaningful capital investment and facility integration work, sterilization facilities, particularly smaller hospital sterile processing departments, face a genuine transition cost even where regulatory compliance ultimately requires the upgrade for ethylene oxide facilities specifically. Low-temperature sterilization method proliferation is a second constraint on monitoring product standardisation, since each low-temperature method, including vaporised hydrogen peroxide and plasma sterilization, requires its own dedicated, clinically validated monitoring product rather than a single universal monitoring solution working across all sterilization methods, meaning monitoring product manufacturers must continuously invest in method-specific product development rather than relying on a single platform serving the full sterilization method landscape. Sterile processing staff training requirements are the third constraint, because transitioning from periodic to continuous monitoring workflow, and from traditional to rapid-read biological indicators, requires staff training and workflow adaptation that not every sterile processing department can implement immediately upon new monitoring technology acquisition, extending the time between technology purchase and full operational realisation of its verification speed benefits. These factors substantially limit sterilization monitoring market growth over the forecast period.

Based on product type, the global sterilization monitoring market is segmented into biological indicators, chemical indicators, and continuous monitoring/recording systems. Biological indicators hold the largest revenue share, because they represent the gold-standard sterility verification method across all major sterilization technologies, which suits leading manufacturers’ established rapid-read biological indicator product lines. Continuous monitoring/recording systems are expected to register the fastest revenue growth rate in the global sterilization monitoring market over the forecast period, driven directly by the EPA’s binding continuous monitoring requirement for ethylene oxide facilities, which is why this category represents the clearest regulatory-mandate-driven growth segment within the broader market.

Rapid-read biological indicator technology is expected to account for a significantly large revenue share in the global sterilization monitoring market during the forecast period

Based on technology, the global sterilization monitoring market is segmented into rapid-read biological indicators and IoT-integrated cycle documentation. Rapid-read biological indicators hold a significant and growing revenue share, reflecting sterile processing departments’ strong preference for same-shift sterility verification over traditional multi-day culture-based alternatives. IoT-integrated cycle documentation is expected to register the fastest revenue growth rate in the global sterilization monitoring market over the forecast period, driven directly by the EPA’s continuous monitoring requirement, which is why this technology category represents the primary beneficiary of the regulatory transition from periodic to continuous verification.

Steam sterilization method is expected to account for the largest revenue share in the global sterilization monitoring market during the forecast period

Based on method, the global sterilization monitoring market is segmented into ethylene oxide, steam, and low-temperature (VHP/plasma) sterilization monitoring. Steam sterilization monitoring holds the largest revenue share, reflecting steam sterilization’s continued position as the most widely used sterilization method across hospital sterile processing departments globally. Ethylene oxide monitoring is expected to register rapid revenue growth in the global sterilization monitoring market over the forecast period, driven directly by the EPA’s new continuous monitoring compliance requirement, which is why this method-specific monitoring category faces the most direct regulatory-driven demand of any segment.

Based on regional analysis, the sterilization monitoring market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the largest concentration of hospital sterile processing departments and contract sterilization facilities globally, and because 3M and STERIS both concentrate significant commercial and product development activity in the country. The EPA’s continuous stationary indoor monitoring requirement applies specifically within the United States regulatory jurisdiction, directly driving domestic ethylene oxide facility monitoring technology adoption ahead of the April 2028 compliance deadline. The concentration of leading sterilization monitoring manufacturers and direct EPA regulatory jurisdiction in the United States also means new continuous monitoring technology adoption is typically most visible in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national sterilization monitoring markets within Europe. The region’s established hospital sterile processing infrastructure and its own evolving ethylene oxide environmental scrutiny under national and EU-level frameworks sustain steady demand. The result is steady rather than rapid growth, shaped by a regulatory environment that parallels, though does not directly mirror, the specific United States EPA continuous monitoring mandate.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and India represent the three largest national sterilization monitoring markets within the region. Expanding hospital sterile processing department infrastructure investment and rising rapid-read biological indicator adoption in China and India are driving new demand from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national sterilization monitoring markets within the region. Hospital sterile processing departments in both countries are gradually adopting rapid-read biological indicator technology, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised monitoring products that Latin American hospitals depend on through 2026, slowing adoption beyond the region’s main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial sterilization monitoring markets within the GCC. The UAE is the most established sterilization monitoring market on the continent given its concentrated private hospital infrastructure, while the wider Gulf states and broader African markets are still building the sterile processing department capacity that monitoring technology adoption depends on.